|
Oxford BioMedica has three products in ongoing clinical trials. Two of these are for the treatment of cancer, TroVax® and MetXia®, and the third product is for the treatment of Parkinson’s disease. The company is currently recruiting for these trials as detailed below.
TROVAX
Phase II Trials
Prostate cancer
- Patients with progressive hormone-refractory prostate cancer
- Open label trial comparing TroVax in combination with docetaxel to docetaxel alone
- The Methodist Hospital in Houston, Texas, USA. (Principal Investigator: Dr Amato, contact Joan Hernandez-McClain, Coordinator, +1 713-441-7943, email jhmcclain@tmhs.org)
METXIA
Phase II Trial
Pancreatic cancer
- Patients with non-resectable pancreatic cancer
- Open label dose escalation trial of MetXia and cyclophosphamide
- The Royal Liverpool University Hospital (Principal Investigator: Professor John Neoptolemos, contact Richard Smith, +44 (0)151 706 4199, r.smith11@liverpool.ac.uk)
- The Sir John McMichael Centre for Clinical Investigation and Research located within the Hammersmith Hospital (Principal Investigator: Professor Robin Williamson, contact Joanna Nicholls +44 (0)20 8383 2273, joanna.nicholls@imperial.ac.uk)
PROSAVIN
Phase I/II Trial
Parkinson’s Disease
- Patients with moderate to late-stage Parkinson’s disease
- Patients will be failing on current treatment with L-DOPA but will not have progressed to drug-induced movement disorders
- Open label dose escalation trail of ProSavin
- Henri MondorHospital, Créteil, France (Principal Investigator: Professor Stephane Palfi, contact +33 (0) 149812203, stephane.palfi@hmn.aphp.fr)
If you are interested in future clinical trials for any of Oxford BioMedica’s products, please email your contact details to enquiries@oxfordbiomedica.co.uk
Website by College Hill - Life Sciences |
